Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
54.26
EV/EBITDA
1.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.3
Face value
--
Shares outstanding
2,059,690
CFO
$-64.79 Mln
EBITDA
$-95.44 Mln
Net Profit
$-63.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NeuroMetrix (NURO)
| 15.4 | 4.1 | 4.8 | 3.5 | -42.7 | -22.4 | -47.8 |
|
BSE Sensex*
| -13.5 | -9.9 | -14.0 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
NeuroMetrix (NURO)
| 10.2 | -69.8 | -70.3 | 58.9 | -26.5 | -43.4 | -55.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic... peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. Read more
Founder, Chairman, CEO, President & Secretary
Dr. Shai N. Gozani M.D., Ph.D.
Founder, Chairman, CEO, President & Secretary
Dr. Shai N. Gozani M.D., Ph.D.
Headquarters
Woburn, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of NeuroMetrix Inc (NURO) is $4.58 (NASDAQ) as of 09-May-2025 09:30 EDT. NeuroMetrix Inc (NURO) has given a return of -42.68% in the last 3 years.
Since, TTM earnings of NeuroMetrix Inc (NURO) is negative, P/E ratio is not available.
The P/B ratio of NeuroMetrix Inc (NURO) is 0.66 times as on 09-May-2025, a 78 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.00
|
0.55
|
|
2023
|
-0.84
|
0.27
|
|
2022
|
-0.33
|
0.06
|
|
2021
|
-5.84
|
0.55
|
|
2020
|
-5.99
|
2.28
|
The 52-week high and low of NeuroMetrix Inc (NURO) are Rs 4.73 and Rs 2.66 as of 02-Apr-2026.
NeuroMetrix Inc (NURO) has a market capitalisation of $ 9 Mln as on 09-May-2025. As per SEBI classification, it is a Small Cap company.
Before investing in NeuroMetrix Inc (NURO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.